It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
The deal, backed by Gavi and executed by UNICEF, could generate up to US$90 million in savings—enough to provide more than 30 million additional doses
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
Clinical trials found that 77% of patients went into remission after receiving obe-cel
The trial tested six injectable doses and three oral doses over as long as 36 weeks
Deceased donor kidney transplants are time-critical, and it is uncommon to attempt them robotically
The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries
Jaypirca is making waves in the fight against B-cell malignancies
The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval
The proposed transaction will be effected as a share swap
Subscribe To Our Newsletter & Stay Updated
